• New research reports that almost half of music fans want virtual concerts to continue
• FDBL’s Fan Pass platform just offered first-ever livestream Halloween concert
• Company’s vision already beginning to redefine artist-fan relationship

Livestreaming concerts are a creative byproduct of the global pandemic, a modern-day solution to the heartbreaking cancellation of live performances and concerts. A new Music 360 report by MRC Data, however, suggests that almost half of music fans want virtual concerts to continue, even after COVID-19 restrictions are eased (https://ibn.fm/CUjyX). That’s music to the ears of Friendable (OTC: FDBL), which just wrapped its first-ever livestreaming Halloween concert, which featured artists S-mack (x2), Mamd, R.T.A and Ball Hog Beats.

“The livestream business has become a necessity since the start of the pandemic,” reported a recent “EDMTunes” article, titled “Half of Music Fans Want Virtual Concerts to Stay” (https://ibn.fm/GgXyI). “Its current prevalent importance has left a positive impact on the industry. This is why virtual concerts are likely to stick around once venues and concert halls resume operations.”

Friendable, a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications, is banking on that being the case. Earlier this year, the company launched its flagship product, the Fan Pass app. Fan Pass is a livestreaming platform that supports artists at all levels, providing exclusive artist-content channels, livestreaming events, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist. The recent Fan Pass Halloween event featured artists who recently approved their artist channels on the Fan Pass platform and now have the ability to schedule, promote and hold virtual events (https://ibn.fm/HbNfF).

“We, along with our friends, family and staff, enjoyed viewing each one of these performances,” said Friendable CEO Robert A. Rositano Jr. “Even more enjoyable was the excitement expressed in discussions centering on all Fan Pass has to offer, and we envision a bright future for the platform and our brand.

“In total, the events generated over 15,933 impressions by approximately 124 users, as well as attracting more than 545 fan interactions with artist content, which continues to show traction and display how our model works,” Rositano continued. “We believe our vision is already beginning to redefine the artist-fan relationship as we push forward to support each artist at every level and work to simultaneously uncover new revenue opportunities for them. Thank you to all our performers, their fans and our shareholders for your support.”

The Halloween event, the first of several holiday-themed livestream events planned for the upcoming season, lasted more than three hours and is available for fans to view via the Fan Pass app or the Fan Pass website using the “Live on Demand” playback feature.

Friendable’s Fan Pass app, artists can offer exclusive content channels to their fans, who simply use their smartphones to gain access to their favorite artists as well as an all-access pass, giving them access to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists — all available to fan subscribers for free on a trial basis. Following the trial, subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, providing VIP access at a fraction of the cost of traditional face-to-face meetups.

For more information about Friendable or the Fan Pass platform, services and offering, visit the company’s website at www.Friendable.com or www.FanPassLive.com.

NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• POAI subsidiary Soluble Biotech’s optimization solution shaves time and cost off of traditional options offered by competition
• Results garnered from company’s HSC optimization are unparalleled in field
• Soluble Biotech lands first major contract, signifying major company milestone

Offering a proprietary automated High Throughput Self-Interaction Chromatography(TM) (“HSC”) Technology Platform, Predictive Oncology (NASDAQ: POAI) provides biomedical and pharmaceutical companies with superior options never before available. A knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, POAI, through its subsidiary Soluble Biotech, delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations.

HSC Technology is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations (https://ibn.fm/vbZ53). The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination of additives and excipients, resulting in increased solubility and physical stability of proteins. And while the technology produces unparalleled optimization results, it provides other benefits as well.

Using current methods, optimization can take more than a year, cost hundreds of thousands of dollars and require teams of five or more individuals to complete. Optimization with HSC, on the other hand, takes only three months, costs tens of thousands of dollars, and needs just one individual to conduct. The comparison is stark — and irresistible. Soluble Biotech has already finalized its first substantial contract since being acquired by POAI earlier this year and is currently negotiating additional contracts (https://ibn.fm/rZyMr).

“Our first contract is a major milestone and validates our recent move into a new, larger facility,” said Soluble Biotech founder Dr. Larry DeLucas, who is also a former NASA astronaut. “We quadrupled our laboratory and office space, some of which will eventually include a GMP facility. Additionally, we acquired state-of-the-art equipment to support our fermentation, therapeutic protein formulation development and protein stability studies.”

A provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes, Soluble Biotech is fast becoming recognized for its expertise in enhancing the drug-development process by rapidly optimizing protein solubility and stability. The company brings proprietary transformational technology to formulation development for protein-based pharmaceuticals and vaccines. In addition, its solubilization and stability technology is used at academic, pharmaceutical and government laboratories involved in conducting fundamental protein research.

Soluble Biotech’s exclusive HSC technology was developed by Dr. William Wilson, a former chairman of the chemistry department at Mississippi State University, and DeLucas; the two have spent almost 20 years developing the game-changing technology and tool. HSC has been validated over the past decade through numerous industry and academic collaborations with several clients seeing tenfold and even hundredfold increases in their protein’s solubility while also maintaining physical stability. For the pharmaceutical sector, this means faster development times and quicker progression of molecules into the clinic. In academics, these results lead to further progression of biochemical and biology studies that are vital to advance fundamental research in areas of unmet medical need.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• National Storm Recovery Inc. acquired Mulch Manufacturing Inc. several months ago to create SGTM
• SGTM diverts storm waste from landfills to create attractive next-generation products that benefit the environment
• Mulch Manufacturing recently secured many new contracts that include The Kroger Co., Circle K, Menards Inc. and Old Castle Lawn & Garden
• SGTM’s Q2 results nearly doubled from previous quarter; include $12.3 million revenue, $3.4 million gross profit

Proving the theory that the whole is greater than the sum of its parts, National Storm Recovery Inc. recently acquired Mulch Manufacturing Inc. to create the Sustainable Green Team (OTC: SGTM) – a leading provider of environmentally-beneficial solutions for tree and storm waste disposal. Besides increased sales, greater profits and international expansion, the synergistic activities of both companies further solidify their shared roles as stewards of the environment through the creation of organic products that benefit nature while diverting natural waste from landfills.

“With Mulch Manufacturing’s national and international distribution, its sales contracts with many big box retailers, and the increase in production and packaging capacity it provides, this strategic acquisition has positioned us as The Sustainable Green Team,” said SGTM CEO Tony Raynor at the time of the acquisition (https://ibn.fm/ct1we).

SGTM primarily provides solutions for the treatment and handling of tree debris created by storms that typically gets sent to disposal sites. Along with creating additional pressure on landfills, this natural waste further increases municipal expenses while contributing to the overall environmental burden experienced across the nation. With over 40 years of combined next-level experience, SGTM provides services that convert this problem into profits by collecting, treating and caring for these trees and transforming them into products that include garden mulch and playground surfacing material.

Besides making good economic sense, the move continues to pay dividends in the form of increased profits – despite the economic recession connected to COVID-19. SGTM just keeps on growing, and part of that growth is attributed to contracts between Mulch Manufacturing and large industry players like The Kroger Co., Circle K, Menards Inc., Old Castle Lawn & Garden, and many more.

“This business combination has created an industry power house; and with our combined strengths, puts us in an ideal position to increase our sales and resulting margins, as our combined operations benefit from the resulting vertical integration and economies of scale,” noted Mulch Manufacturing CEO Ralph Spencer.

Management forecasts at the time of the acquisition have materialized with better results than expected. SGTM’s profits nearly doubled in a quarter, leading to impressive Q2 results that include $12.3 million in revenue and $3.4 million in gross profit (https://ibn.fm/ySmKU). Along with the increased contracts from Mulch Manufacturing, much of this growth can also be attributed to relief efforts in the wake of Hurricane Laura along with new contracts between SGTM’s strategic partners and state municipalities.

STGM’s strong commitment to environmental sustainability served as a primary motivation behind the name and ticker change from National Storm Recovery Inc. (OTC: NSRI) to Sustainable Green Team, Ltd. (OTC: SGTM). Along with driving forward its environmental mission, the company is also committed to maximizing shareholder value, particularly for investors looking to leverage profitable – and ethical – opportunities during times of economic uncertainty.

To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/OSR73.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Knightscope is a leader in the development of autonomous security capabilities and is on target to disrupt the $500 billion security industry
• The company is presently in the process of raising up to $25 million in additional growth capital as it prepares for a possible public listing
• With more than 16,000 investors, over $70 million raised since inception and several Fortune 1000 clients with prepaid contracts, Knightscope is poised to be an industry leader in the future of public safety and security
• The company has opened investing to the public through its latest Reg A+ offering at $10 per share
• This innovation has the potential to drive cost savings and profitability for clients; manufacturing costs can be recovered as soon as the first year of operation
• The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs; the machines’ embedded thermal scanning capabilities also aided in preventing the breakout of a major fire

Knightscope Inc., founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities on target to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics and artificial intelligence.

Knightscope designs and builds Autonomous Security Robots (“ASRs”) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country, despite the pandemic (note: robots are immune).

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.Knightscope.com/Crime

The company has achieved several milestones since its creation in 2013, including:

• Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology;
• Operating for more than one million hours in the field and securing contracts across five time zones;
• Navigating through the global pandemic without interruption by continuing to operate on a daily basis across the nation and supporting clients classified as essential services; and
• Continuing its hiring processes despite the current societal and economic disruption.

Growth Capital

With backing from more than 16,000 investors and four major corporations and over $70 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

The company is presently in the process of raising up to an additional $25 million in growth capital as it prepares for a potential public listing. Knightscope has reserved ticker symbol ‘KSCP’ with Nasdaq.

Investors can buy shares exclusively through the company’s managing broker-dealer, StartEngine.

Knightscope’s latest Reg A+ offering is for up to 2.5 million shares of Series S preferred stock convertible into shares of Class A common stock at a price to the public of $10 per share.

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country.

Crime has a negative economic impact in excess of $1 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was recently interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one to one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $4 to $11 per hour, compared with approximately $85 and $30 per hour for an armed off duty law enforcement officer and an unarmed security guard, respectively.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has eight patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’.

The ASRs and all the related technologies were developed ground up by the Company and are Made in the USA.

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

For more information, visit the company’s website at www.Knightscope.com

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight 

Episode 132 of the Wild West Crypto Show carries on its mission of preaching the value consumers can find in alternative currencies, even during seasons of social and financial unrest. Hosts Drew Taylor and Brent Bates pepper their podcast commentary about the state of the cryptocurrency industry with observations about business activity, U.S. politics and even evangelical prophecy, all with Texas-flavored humor undergirding their interviews.

The episode, titled, “Cryptos Always Run When We Interview Bo!” refers to the pair’s interview with Biblical cycle and financial analyst Bo Polny, who uses his insights on market timing to anchor the final portion of the 50-minute show.

Along the way, Taylor and Bates also speak with Adrian Crion, the founder and CEO of Germany-based Spielworks, an onboarding company dedicated to bringing users, specifically mass-market gamers, onto blockchain. And Chris Davis, the CTO of Film.Io, talks about his platform for getting unknown filmmakers on a level playing field with more established industry insiders by helping them build a mass-market audience America’s Got Talent-style, so that when they are prepared to make a pitch to studios or financial backers they can show that they’ve already built significant audience interest.

CryptoCurrencyWire Communications Director Jonathan Keim is a show regular, offering additional insights on crypto space news headlines from around the world. In this episode, Keim acknowledges new signs that alternatives to the dollar are gaining mainstream recognition.

When Cointelegraph reported that U.S. Currency Comptroller Brian Brooks stated that decentralized finance movements will spawn “inevitable” change and will render many of the services banks provide obsolete, “just as email disrupted the postal service,” Keim called it a sign that “everybody is waking up” to a fact that he and the show’s hosts have previously discussed many times.

“It’s just exciting when you hear people like Brian Brooks say these kinds of things. We’re seeing so much movement in this past year. It’s really insane. And not just here in the U.S. but abroad as well,” Keim added.

Keim also noted that the chairman of the U.S. Federal Reserve has said its financial institutions aren’t in a hurry to introduce central bank digital currency, which prompted Morgan Creek Digital co-founder Anthony Pompliano to argue that time is of the essence and if it doesn’t act “the U.S. is going to fall really far behind China because it all comes down to accessibility.”

“In our small town, we have a bank and a chicken place on every corner and a convenience store across the street. We’ve got plenty of all that sort of stuff,” Bates quipped. “The U.S. getting involved in this is going to help all those unbanked people and is going to help all these other economies by being able to provide liquidity and everything that the U.S. dollar and digital dollar could bring.”

Bates expressed excitement at news that crypto gaming pioneer Cloudbet is adding Pax Gold coin to its platform to make betting with gold backing possible in a first for the gaming world.

“You can’t carry all your gold with you. It becomes heavy and kind of hard to lug around,” Bates said. “You take that little thumb drive around with you, it could have a billion dollars or it could have 59 cents and everything in between. It’s so much more pragmatic for it to be digitized and to carry around a piece of it.”

Keim said what he finds so interesting is that there are so many alternatives to the dollar “springing up all over the place” as means for currency transactions.

“This world-first accomplishment is only feasible because a gold-backed crypto is easily divisible and easier to exchange,” he said.

The Wild West Crypto Show podcast appears online and in multiple markets across the country. Bates’ and Taylor’s purpose is to educate people about alt-currencies “so that they’re not afraid of it.”

To view the latest episode, which includes CryptoCurrencyWire’s ongoing segment featuring recent news from around the world, visit hhttps://ibn.fm/3wzvf.

• VistaGen has three innovative CNS drug candidates which target a wide range of anxiety, depression and neurological disorders
• PH94B, the Company’s most advanced drug candidate, is entering Phase 3 development for acute, on-demand treatment of social anxiety disorder
• Company sees potential to displace benzodiazepines currently being used to treat multiple anxiety disorders
• Strategy has gained in importance after U.S. FDA announced in late-September its update requirement for boxed warnings on all benzodiazepines to highlight risks of abuse, misuse, addiction, and physical dependence
• Benzodiazepine epidemic is as worrisome as the opioid epidemic – 92 million benzodiazepine prescriptions in 2019 according to the FDA

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications which go beyond the standard of care for anxiety, depression, and several neurological disorders. The company’s product portfolio consists of three novel drug candidates which seek to target a wide variety of central nervous system (“CNS”) disorders through medications with potential to not only be effective but also present fewer side-effects and safety concerns relative to the current standard of care. Its initiative relating to anxiety disorders has unique potential to pay dividends following recent actions taken by the U.S. Food and Drug Administration (“FDA”) involving benzodiazepines, a class of drugs widely used to treat anxiety disorders, as well as insomnia and seizures.

In late September 2020, the FDA announced that it would require the boxed warning on all benzodiazepines to be updated to describe the risks of abuse, misuse, addiction, physical dependence and withdrawal reactions consistent to all medicines in this class (https://ibn.fm/sHdvF).

A review carried out by the FDA found that benzodiazepines were widely prescribed in the U.S., with 92 million prescriptions in 2019, often for extended periods of time. The study also found that benzodiazepines were widely abused and misused, often together with alcohol, prescription opioids, and illicit drugs—all of which could result in serious issues. Separately, the FDA study also revealed that some patients were found to have suffered serious withdrawal reactions after benzodiazepines were stopped suddenly or the dose reduced quickly, with a significant minority experiencing difficult withdrawal symptoms for several months.

With its lead drug candidate, PH94B, entering Phase 3 development in 2021, VistaGen Therapeutics is focused on displacing benzodiazepines in the treatment paradigm for the acute treatment of social anxiety disorder, as well as many other anxiety disorders.

The global CNS therapeutics market is estimated to reach $130 billion by 2025 and has been forecast to grow at a CAGR of more than 5.93% between 2018-2025. A rise in mental illnesses and increased awareness of psychiatric disorders (https://ibn.fm/I0JiR), conditions which have been exacerbated during the COVID-19 pandemic, have been calculated to cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://ibn.fm/53t2R).

The impact of mental health disorders on patient lives and the wider global economy, coupled with the potential risks associated to conventional benzodiazepine drugs, have increased the urgent need for pharmaceutical companies to develop more effective and safer alternatives to the current standard of care available to patients today. As such, VistaGen has taken it upon itself to help address the millions of underserved patients suffering from anxiety and depression disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders (https://ibn.fm/UyTmK).

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

• Since its launch in early 2019, Sequire has gained 1 million active investors, traders from 91 public companies
• New name — Sequire — represents platform’s main objective to acquire, secure investors for publicly traded companies
• Intelligent technologies set Sequire apart in world of data collection, reinforce Company’s focus on innovation and uniqueness

Consumer data—quickly becoming one of the most sought-after commodities in the world today—has never been so valuable. In response to this demand for consumer information, the investor intelligence and communications platform created by SRAX (NASDAQ: SRAX) unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies, allowing those issuers to use audience insights to capture the interest of existing investors and attract new investors. Since its launch in early 2019, Sequire has gained 1 million active investors and traders from 91 public companies (https://ibn.fm/CDFUJ). Originally named SRAX IR, the investor intelligence platform was renamed Sequire earlier this year; the powerful name represents the platform’s main objective to acquire and secure investors for publicly traded companies (https://ibn.fm/b8IvN). “We are thrilled to announce the new brand, giving the platform its own identity separate from SRAX,” said SRAX founder and CEO Christopher Miglino. “It’s also arriving at an opportune time as we are developing new intelligent technologies to further provide public companies the tools to reach and engage their shareholders.” These new intelligent technologies set Sequire apart in the world of data collection and reinforce the company’s focus on innovation and uniqueness in the marketplace (https://ibn.fm/Ko2ZH). For instance, Sequire enables its customers to engage with consumers in ways they’ve never been able to before, including the following:

• Know who’s buying and selling by unlocking key shareholder behaviors and trends from company data sets.
• Monitor training data in real time and obtain real-time market data, including level-two trading data, current sharing prices, volume, % change, and more; see biggest gains and losses over periods of time.
• Manage warrants and monitor expiring, outstanding warrants.
• Build full contact profiles on shareholders, including emails, phone numbers and social media accounts; engage with them directly in the platform.

In addition to these intelligent technologies, Sequire offers consumers a variety of options and tools that support them in their efforts to grow (https://ibn.fm/MkStN). Those include the following:

• A stock-for-ads program that includes a subscription to Sequire and credit for paid media in exchange for stock; designed as a way to help public companies engage with customers or clients and preserve cash during critical times.
• A virtual road show where companies can host one-on-one or one-to-many video and audio meetings to present their stories to new shareholders and provide quarterly and annual shareholder updates. After an event has ended, companies can track individuals who attended and monitor their investments in the company in real time.
• A mobile app that clients can use to monitor their shareholders’ behaviors wherever they go; the company intends to expand this feature set for both the desktop and mobile applications.

As the platform grows, Sequire’s ability to better understand which types of investors are willing to buy different stocks becomes increasingly defined, thus enabling the Company to better serve its clients. SRAX is building the largest and most reliable opted-in data sets across many industry verticals, accurately identifying target consumers for brands and companies in the CPG, investor relations, luxury, and lifestyle spaces, keeping those brands ahead in the competitive curve with high-quality data. As the company’s most recent offering, Sequire is a premiere investor intelligence and communications management platform that unlocks investor behaviors and trends, including who is buying and selling stock. Through the platform, companies can track their investors’ behaviors and trends and use those rich audience insights to engage existing investors and attract new investors across marketing channels. For more information about SRAX and Sequire, visit the companies’ websites at www.SRAX.com and www.MySequire.com, NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX 

• The Investor Summit Group’s Virtual Fall Summit will take place Nov. 16 through 18, providing a tried-and-tested formula for informing IR managers and investment-capitalized interests about available opportunities
• The summit provides a balance of market sectors in play, trending most heavily toward healthcare, consumer, financial and technology with energy, cannabis, industrial, and blockchain also represented
• Networking opportunities include live Q&A sessions, portal messaging and a virtual happy hour feature
• Summit organizers ensure quality investors through an eight-step vetting process and provide business attendees with concierge service in establishing a presentation and 1×1 schedule so attendees can “just show up”

The Investor Summit Group will present its tried-and-tested model for engaging business growth opportunities during its annual Fall Summit, which will take place via virtual means Nov. 16 to 18 for registered attendees.

Quality investors are the lifeblood of any public company, providing life-giving sustenance during growth phases particularly. The advent of the worldwide COVID-19 pandemic has altered the once-familiar networking corridors of investor relations, driving business management teams to question the need to jump on an airplane for face-to-face meetings whenever opportunities present themselves.

Investor Summit Group is experienced at delivering informational and networking opportunities that rely on quality connections through the utility of interactive online technology.

“While many investor conferences have transitioned to virtual format in recent weeks, The Investor Summit was far more of a success than others. I had a full slate of 1x1s, a well-attended presentation and no issues with the conferencing lines or other virtual aspects of the conference,” Ur-Energy Inc. Chairman and CEO Jeff Klenda wrote in one testimonial after an Investor Group event during the summer.

The summit provides the opportunity for IR managers and investment capital to discuss relevant topics in the investment space, delivering a concierge experience with hand-picked executives and vetted investors. Investor Summit uses an eight-step process to vet investors and guard against service providers posing as buy-side business.

The summit backs up its brand with a guarantee of a 50 percent-off ticket to a future conference if a business secures less than four meetings, and a $500 credit toward a future conference if any member of the investor pool turns out to be a falsely identified service provider.

The summit’s networking opportunities include interactions through live Q&A sessions, portal messaging and a virtual happy hour feature that includes stock pitches, round tables and lounge areas for organic interactions.

In delivering its concierge service, Investor Summit Group’s scheduling team calls qualified investors and builds company agendas. The virtual presentation is streamed live to investors and any other interests the company may wish to share its unique proposition with, and the presentations are accessible online for up to two months after the event to keep opportunities open.

Attendees can choose informational talks and set up meetings beginning three weeks ahead of the event, and the conference concierge team is available to help with planning.

Interested companies and individuals can register for the online summit by visiting www.InvestorSummitGroup.com.

• PwC’s Digital Trend Outlook 2020: Esports offers strategic, financial investors opportunity to see sustainable returns from the industry
• Investors should act now if they want to participate in the esports market
• Mobius Interactive poised to leverage growing interest of investors eyeing esports potential

In its report focusing on esports, the global consultancy firm PwC states that investors should act now if they want to invest in the esports market. As a company dedicated to bringing together loyalty programs, targeted gamification and product merchandising into one seamless package targeting the 18- to 38-year-old esports community, Mobius Interactive is poised to capitalize on a growing industry that looks to be well on its way to becoming mainstream.

The Digital Trend Outlook 2020: Esports report notes that, despite increasing consumer demand, investors are still reserved due to a lack of knowledge about the ecosystem of esports (https://nnw.fm/x9v9y). (https://ibn.fm/iaEcO). But COVID-19 has changed that, accelerating esports’ movement to mainstream and raising the sector’s visibility.

Esports turned online gaming into a spectator sport, growing considerably since its humble beginnings. Overcoming physical and spatial limitations of traditional sports, esports has exploded in the wake of the pandemic as it relies on digital platforms rather than actual presence.

Although still in its infancy, esports shows strong potential to monetize the growing and highly engaged fan base by generating revenues through multiple channels, including media rights, sponsorships, advertising agreements, publisher fees, merchandise sales, and streaming.

The economics of esports is superior to that of traditional sports. The Digital Trend Outlook research reports that the revenue side of the sector has an explosive scale with attractive costs per broadcast. These compelling features, combined with the changed consumer behavior and restrictive social distancing measures due to the virus outbreak, catapulted esports into the spotlight of the international funding scene.

In June, esports-related companies reported $196.8 million in investments, totaling $1.1 billion of disclosed investments this year to date. Recognizing a significant misconception about this growing sector among the broader investor audience, the consultancy firm states that it is crucial to educate stakeholders about the esports ecosystem and how the industry generates profits.

The industry is evolving as leading investors have started teaming up with top consulting firms to understand the esports market and learn how to benefit from it effectively. PwC believes that both strategic and financial investors have the opportunity to see sustainable returns from the industry.

As an online gaming operator featuring a variety of unique offerings catering to diverse demographic groups, Mobius Interactive is well positioned to leverage the growing interest as smart money is increasingly betting on esports. The company is partnering with award-winning eSports and iGaming platform Ultra Play and more than 600 VIP and master-gaming affiliates seeking to attract high-net-worth gamers worldwide. Led by management with experience in eSports and handling the launches of more 30 successful products within the last three years, Mobius Interactive is set out to become a notable player in this growing sector.

For more information, visit the company’s website at www.MobiusInteractive.Ltd.

NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Brain Scientific is a commercial-stage health care company aiming to modernize the brain diagnostics market by employing cutting edge technologies to bridge the widening gap in access to neurological care
• The company’s current offerings are the NeuroCap(TM) and NeuroEEG(TM) – two FDA-cleared devices delivered by wholly owned subsidiary MemoryMD Inc.
• The company’s intellectual property portfolio includes three patents in the U.S., China and Europe
• Brain Scientific is developing new products, including disposable EEG headsets for pediatric patients, long-term monitoring solutions and artificial intelligence options for monitoring and recording brain activity
• The company was selected as a finalist at the 2020 Epilepsy Foundation Shark Tank Competition
• The EEG device market is currently estimated at $956.1 million and is expected to grow to $1.6 billion by 2026, achieving a CAGR of 8.7%
• In the future, Brain Scientific intends to leverage AI and machine learning to map brain activities and providing data about different neurological conditions such as dementia, pre-Alzheimer’s and epilepsy

Brain Scientific (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (“EEG”) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (“EUA”) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

• NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

• NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

• NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
• NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

• Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
• An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

For more information, visit the company’s website at www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF